Market Place
Sourcing Support
Neuron23 Doses NEU-111 in Phase 1 Immune Disorder Trial
03 Dec 2024 //
BUSINESSWIRE
Neuron23 to Use Roche’s Digital Biomarker in Parkinson’s Trial
19 Nov 2024 //
BUSINESSWIRE
Neuron23 Unveils Phase 2 Trial in Early Parkinson’s Disease
19 Nov 2024 //
BUSINESSWIRE
Neuron23 Appoints Andrew Yost, MBA, as Chief Business Officer
22 Aug 2023 //
PR NEWSWIRE
Qiagen to develop companion diagnostic for Parkinson’s drug
17 Sep 2022 //
FIERCEBIOTECH
QIAGEN & Neuron23 Partner to Develop Diagnostic for Novel Parkinson’s Drug
14 Sep 2022 //
BUSINESSWIRE
Neuron23 Appoints Kathy Dong, Pharm.D., MBA to Board of Directors
14 Jun 2022 //
PRNEWSWIRE
Neuron23 Appoints Sam Jackson, M.D., MBA, as Chief Medical Officer
12 Apr 2022 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.